Publications
Publications
Show Results For
- All HBS Web
(154)
- Faculty Publications (11)
biology
→
Page 1 of 11
Results
- October 2022 (Revised May 2023)
- Case
Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues
Ginkgo Bioworks, a synthetic biology company based in Boston, Massachusetts, faced divergent views on its revenue possibilities and accounting practices. After a report emerged accusing it of fraudulent accounting and lack of innovation, its share price plunged. But... View Details
- September 15, 2021
- Article
Improving Deconvolution Methods in Biology Through Open Innovation Competitions: An Application to the Connectivity Map
By: Andrea Blasco, Ted Natoli, Michael G. Endres, Rinat A. Sergeev, Steven Randazzo, Jin Hyun Paik, N.J. Maximilian Macaluso, Rajiv Narayan, Xiaodong Lu, David Peck, Karim R. Lakhani and Aravind Subramanian
A recurring problem in biomedical research is how to isolate signals of distinct populations (cell types, tissues, and genes) from composite measures obtained by a single analyte or sensor. Existing computational deconvolution approaches work well in many specific... View Details
- October 2019 (Revised November 2019)
- Case
C16 Biosciences: Lab-Grown Palm Oil
By: Jeffrey J. Bussgang and Olivia Hull
Synthetic biology start-up C16 Biosciences wants to solve a big problem: replace palm oil, a major contributor to deforestation and climate change, with a lab-grown substitute. CEO Shara Ticku has ambitious plans to supply her lab-grown palm oil to food manufacturers,... View Details
- Article
Advancing Computational Biology and Bioinformatics Research Through Open Innovation Competitions
By: Andrea Blasco, Michael G. Endres, Rinat A. Sergeev, Anup Jonchhe, Max Macaluso, Rajiv Narayan, Ted Natoli, Jin H. Paik, Bryan Briney, Chunlei Wu, Andrew I. Su, Aravind Subramanian and Karim R. Lakhani
Open data science and algorithm development competitions offer a unique avenue for rapid discovery of better computational strategies. We highlight three examples in computational biology and bioinformatics research where the use of competitions has yielded significant... View Details
- August 2019
- Case
Synthetic Biology Investment Opportunity
By: Peter Barrett, Karim R. Lakhani, Julia Kelley and Kerry Herman
Using an overview of the emerging technology of Synthetic Biology, this case provides the basis for discussion on what questions one would ask in evaluating a potential investment in the field. View Details
- February 2015
- Article
'Open' Disclosure of Innovations, Incentives and Follow-on Reuse: Theory on Processes of Cumulative Innovation and a Field Experiment in Computational Biology
By: Kevin J. Boudreau and Karim R. Lakhani
Most of society's innovation systems―academic science, the patent system, open source, etc.―are "open" in the sense that they are designed to facilitate knowledge disclosure among innovators. An essential difference across innovation systems is whether disclosure is of... View Details
- Other Article
Prize-based Contests Can Provide Solutions to Computational Biology Problems
By: Karim R. Lakhani, Kevin J. Boudreau, Po-Ru Loh, Lars Backstrom, Carliss Y. Baldwin, Eric Lonstein, Mike Lydon, Alan MacCormack, Ramy A. Arnaout and Eva C. Guinan
- March 2011 (Revised June 2012)
- Case
Office of Technology Transfer - Shanghai Institutes for Biological Sciences
By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland
Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing... View Details
- February 2010
- Case
Amyris Biotechnologies: Commercializing Biofuel
By: Gary P. Pisano and Alison Berkley Wagonfeld
In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic biology to convert sugarcane into both renewable fuels and renewable chemicals. The Amyris' marketing team was investigating the commercial interest for both types of products, while the... View Details
- April 2002
- Case
In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen
By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok
Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed... View Details
- 2001
- Chapter
Publicly Funded Science and the Productivity of the Pharmaceutical Industry
By: Rebecca Henderson and Ian Cockburn
U.S. taxpayers funded $14.8 billion of health related research last year, four times the amount that was spent in 1970 in real terms. In this paper we evaluate the impact of these huge expenditures on the technological performance of the pharmaceutical industry. While... View Details